A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors

Transfusion

Volumn 57, Issue 3, 2017, Pages 823-831

  Brambilla, Donald J ^a   Busch, Michael P ^b   Dodd, Roger Y ^c   Glynn, Simone A ^d   Kleinman, Steven H ^e  

^a RTI INTERNATIONAL   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c AMERICAN RED CROSS   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; REPEAT PROCEDURE; BIOLOGICAL MODEL; CONTROLLED STUDY; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; RANDOMIZED CONTROLLED TRIAL;

BLOOD DONORS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MODELS, BIOLOGICAL;

EID: 85006325307     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13939     Document Type: Article

References (18)

1. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685–90.
2. Kleinman S, Busch MP, Korelitz JJ, et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted HIV and HCV infection. Transfus Med Rev 1997;11:155–72.
3. Wang B, Schreiber GB, Glynn SA, et al. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors?. Transfusion 2005;45:1089–96.
4. Adeoti FM, Oyourou AO, Sirancy BL, et al. Evolution of the residual risk of transmitting HIV, HCV and HBV in the blood transfusion from 1998 to 2009 in Cote d'Ivoire. J Vaccines Vaccin 2012;3:1–4.
5. Mapako T, Mvere DA, Chitiyo ME, et al. Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety. Transfusion 2013;53:2413–21.
6. Zou S, Musavi F, Notari EP, et al. Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008. Transfusion 2010;50:1487–94.
7. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495–504.
8. Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003;169:767–73.
9. O'Brien SF, Yi QL, Fan W, et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007;47:316–25.
10. O'Brien SF, Yi Q-L, Fan W, et al. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012;103:83–6.
11. Shaer LA, AbdulRahman M, John TJ, et al. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009. Transfusion 2012;52:2300–9.
12. Sabino EC, Gonçalez TT, Carneiro-Proietti AB, et al. Human immunodeficiency virus prevalence, incidence, and residual risk of transmission by transfusions at Retrovirus Epidemiology Donor Study-II blood centers in Brazil. Transfusion 2012;52:870–9.
13. de Almeida-Neto C, Sabino EC, Liu J, et al. Prevalence of serological markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus. Transfusion 2013;53:827–34.
14. Soldan K, Barbara JAJ, Ramsay ME, et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003;84:274–86.
15. Niederhauser C, Schneider P, Fopp M, et al. Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003. Euro Surveill 2005;10:2:14–6.
16. Lefrère JJ, Dahourouh H, Dokekias AE, et al. Estimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study. Transfusion 2011;51:486–92.
17. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721–5.
18. Wang J, Liu J, Yao F, et al. Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus types 1 and 2 infection among Chinese blood donors. Transfusion 2013;53:1240–9.